SomnoMed’s record quarter

Strong performances in the US and Europe have underpinned a record quarter for this maker of mandibular splints – and it looks like there's more to come.

SomnoMed’s share price has increased 114% since we upgraded the company in SomnoMed: A future mini-ResMed? on 5 Feb 14 (Speculative Buy – $1.33) and made the case for why substantial growth lay ahead. With revenue for the six months to 31 December increasing 18% to $14.8m, that investment case remains on track.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles